MarketCap
Facebook
X
TelegramQuarterly report 2024-Q3
added 11-19-2024
Renalytix AI plc Operating Income 2011-2026 | RNLX
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Renalytix AI plc
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -29.6 M | -42.2 M | -53.2 M | -31.9 M | -10.3 M | -42.3 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -10.3 M | -53.2 M | -34.9 M |
Quarterly Operating Income Renalytix AI plc
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.09 M | - | -6.55 M | -8.64 M | -8.89 M | - | -10.9 M | -9.65 M | -11.7 M | - | -14.5 M | -13.8 M | - | - | -8.07 M | -8.61 M | - | - | - | - | - | - | - | - | - | -567 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -567 K | -14.5 M | -8.84 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
1.35 B | $ 116.92 | 2.67 % | $ 35.5 B |  USA |
 |
Aspira Women's Health
AWH
|
-7.91 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
-33.3 M | $ 1.18 | 0.85 % | $ 6.43 M | USA |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
CareDx, Inc
CDNA
|
-30.8 M | $ 17.92 | 1.41 % | $ 955 M | USA |
 |
Exact Sciences Corporation
EXAS
|
-206 M | - | - | $ 19.8 B | USA |
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 16.24 | 0.93 % | $ 175 M |  China |
 |
Co-Diagnostics
CODX
|
-50.2 M | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Interpace Biosciences
IDXG
|
4.08 M | $ 1.98 | -0.63 % | $ 8.76 M | USA |
 |
Illumina
ILMN
|
-833 M | $ 128.0 | 1.23 % | $ 20.4 B | USA |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M | USA |
 |
Castle Biosciences
CSTL
|
8.67 M | $ 25.19 | 1.45 % | $ 700 M | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M | China |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
Laboratory Corporation of America Holdings
LH
|
1.38 B | $ 274.72 | 2.06 % | $ 22.9 B | USA |
 |
Charles River Laboratories International
CRL
|
25.2 M | $ 175.07 | 3.26 % | $ 8.68 B | USA |
 |
Medpace Holdings
MEDP
|
535 M | $ 520.65 | 2.39 % | $ 15 B | USA |
 |
Danaher Corporation
DHR
|
4.69 B | $ 196.19 | 2.71 % | $ 140 B | USA |
 |
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K |  Israel |
 |
Myriad Genetics
MYGN
|
-387 M | $ 4.77 | 0.63 % | $ 442 M | USA |
 |
Neogen Corporation
NEOG
|
-1.06 B | $ 10.34 | 3.61 % | $ 2.24 B | USA |
 |
National Research Corporation
NRC
|
22.6 M | $ 17.26 | 1.29 % | $ 386 M | USA |
 |
Natera
NTRA
|
-541 M | $ 210.83 | 0.75 % | $ 20.7 B | USA |
 |
Invitae Corporation
NVTA
|
-94.9 M | - | - | $ 21.2 M | USA |
 |
Organovo Holdings
ONVO
|
-12.6 M | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
325 K | - | -16.95 % | $ 1.54 M | USA |
 |
Fulgent Genetics
FLGT
|
-73.9 M | $ 15.83 | -0.5 % | $ 479 M | USA |
 |
Pacific Biosciences of California
PACB
|
-554 M | $ 1.47 | 2.08 % | $ 441 M | USA |
 |
Guardant Health
GH
|
-437 M | $ 92.84 | -0.49 % | $ 11.6 B | USA |
 |
PerkinElmer
PKI
|
357 M | - | -0.91 % | $ 14.7 B | USA |
 |
QIAGEN N.V.
QGEN
|
466 M | - | - | $ 10.6 B |  Niderland |
 |
Psychemedics Corporation
PMD
|
-2.92 M | - | -1.84 % | $ 15.3 M | USA |
 |
Personalis
PSNL
|
-68.3 M | $ 6.33 | 2.59 % | $ 375 M | USA |
 |
Anixa Biosciences
ANIX
|
-11.7 M | $ 2.73 | 1.49 % | $ 88.6 K | USA |
 |
Biomerica
BMRA
|
-5.14 M | $ 2.15 | -0.46 % | $ 4.94 M | USA |
 |
Quotient Limited
QTNT
|
-82.7 M | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 106.54 | -0.58 % | $ 8.79 B |  Irlanda |
 |
Check-Cap Ltd.
CHEK
|
-25.9 M | - | - | $ 9.42 M | Israel |
 |
Celcuity
CELC
|
-172 M | $ 116.94 | 1.19 % | $ 5.47 B | USA |